High reported treatment satisfaction in people with type 1 diabetes switching to latest generation insulin pump regardless of previous therapy.

Published

Journal Article

The effects of transition by individuals with type 1 diabetes (T1D) to more recently available continuous glucose monitoring (CGM)-enabled insulin pumps from either multiple daily insulin injections (MDI) or older insulin pumps on treatment satisfaction have not been well studied. We conducted a survey to assess treatment satisfaction among users of the Animas(®) Vibe™ insulin pump, a latest generation insulin pump (LGIP) system (CGM-enabled), after switching from MDI or earlier generation insulin pumps. Individuals with T1D from 141 centers in 5 countries and 4 language areas participated in the survey. Treatment satisfaction was assessed by the Insulin Treatment Satisfaction Questionnaire (ITSQ), which was included in a 50-item online questionnaire that also assessed preference for using the LGIP compared with previous treatment and satisfaction with key LGIP features. A total of 356 individuals, ages 12-79 years, responded to the survey: mean (SD) age 38.4 (16.1) years; diabetes duration 19.1 (13.3) years; female 59%; previously treated with MDI 58%. Overall mean (SD) ITSQ scores were high among all respondents regardless of prior treatment: 95.1 (23.2) (scale: 0-132). No differences between previous-treatment groups were seen. Most (83%) of respondents rated the LGIP to be better than their previous insulin delivery system: "much better" (65%), "a bit better" (18%) regardless of age, and 95% would recommend using the LGIP to others. Use of the Animas Vibe was associated with high treatment satisfaction and perceived as a better method of insulin delivery regardless of previous insulin therapy or age.

Full Text

Duke Authors

Cited Authors

  • Barnard, KD; Bromba, M; de Lange, M; Halbron, M; Levy, BL; Lévy, M; Lippmann-Grob, B; Walshe, K; Ziegler, R

Published Date

  • March 2015

Published In

Volume / Issue

  • 9 / 2

Start / End Page

  • 231 - 236

PubMed ID

  • 25591855

Pubmed Central ID

  • 25591855

Electronic International Standard Serial Number (EISSN)

  • 1932-2968

Digital Object Identifier (DOI)

  • 10.1177/1932296814567893

Language

  • eng

Conference Location

  • United States